Ireland - English - HPRA (Health Products Regulatory Authority)

cz vaccines s.a.u. - purified protein derivative from culture of mycobacterium bovis, strain an-5 - solution for injection - 2500 international units/dose - bovine tuberculin ppd - cattle - immunological

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - azithromycin dihydrate, quantity: 524 mg - tablet, film coated - excipient ingredients: lactose monohydrate; hypromellose; triacetin; calcium hydrogen phosphate; titanium dioxide; pregelatinised maize starch; crospovidone; sodium lauryl sulfate; magnesium stearate - azithromycin is indicated for use in adults for the treatment of the following infections of mild to moderate severity:,1. lower respiratory tract infections:,acute bacterial bronchitis due to streptococcus pneumoniae, haemophilus influenza or moraxella catarrhalis.,community acquired pneumonia due to streptococcus pneumoniae or haemophilus influenzae in patients suitable for outpatient oral treatment.,community acquired pneumonia caused by susceptible organisms in patients who require initial intravenous therapy. in clinical studies efficacy has been demonstrated against chlamydia pneumoniae, haemophilus influenzae, legionella pneumophilia, moraxella catarrhalis, mycoplasma pneumoniae, staphylococcus aureus and streptococcus pneumoniae.,2. upper respiratory tract infections:,acute sinusitis due to streptococcus pneumoniae or haemophilus influenzae.,acute streptococcal pharyngitis. note: penicillin is the usual drug of choice in the treatment of streptococcus pyogenes pharyngitis, including the prophylaxis of rheumatic fever. azithromycin appears to be almost as effective in the treatment of streptococcal pharyngitis. however, substantial data establishing the efficacy of azithromycin in the subsequent prevention of rheumatic fever are not available at present.,3. uncomplicated skin and skin structure infections:,uncomplicated infections due to staphylococcus aureus, streptococcus pyogenes or streptococcus agalactiae. abscesses usually require surgical drainage.,4. sexually transmitted diseases: uncomplicated urethritis and cervicitis due to chlamydia trachomatis.,note: at the recommended dose azithromycin cannot be relied upon to treat gonorrhoea or syphilis. as with other drugs for the treatment of non-gonococcal infections, it may mask or delay the symptoms of incubating gonorrhoea or syphilis. appropriate tests should be performed for the detection of gonorrhoea or syphilis and treatment should be instituted as required.,azithromycin is also indicated for the treatment of chlamydia trachomatis conjunctivitis and trachoma.,azithromycin is also indicated for the prevention of infection due to mycobacterium avium-intracellulare complex (mac) disease, when used as the sole agent or in combination with rifabutin at its approved dose, in adults and children aged more than 12 years with hiv infection and cd4 cell count less than or equal to 75 cells/?l (see precautions). disseminated infection due to mycobacterium avium-intracellulare complex should be excluded by a negative blood culture prior to commencement of therapy.,azithromycin is indicated for use in children for the treatment of the following infections:,1. acute streptococcal pharyngitis/tonsillitis:,note: penicillin is the usual drug of choice in the treatment of streptococcus pyogenes pharyngitis, including the prophylaxis of rheumatic fever. the 20 mg/kg azithromycin dose appears to be as effective as penicillin in the treatment of streptococcal pharyngitis. however, substantial data establishing the efficacy of azithromycin in the subsequent prevention of rheumatic fever are not available at present.,2. chlamydia trachomatis conjunctivitis and trachoma in children 12 months or older.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - azithromycin dihydrate, quantity: 524.1 mg (equivalent: azithromycin, qty 500 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; sodium starch glycollate type a; magnesium stearate; maize starch; sodium lauryl sulfate; lactose monohydrate; hypromellose; titanium dioxide; macrogol 4000 - azithromycin is indicated for use in adults for the treatment of the following infections of mild to moderate severity: 1. lower respiratory tract infections: acute bacterial bronchitis due to streptococcus pneumoniae, haemophilus influenzae or moraxella catarrhalis.community acquired pneumonia due to streptococcus pneumoniae or haemophilus influenzae in patients suitable for outpatient oral treatment. community acquired pneumonia caused by susceptible organisms in patients who require initial intravenous therapy. in clinical studies efficacy has been demonstrated against chlamydia pneumoniae, haemophilus influenzae, legionella pneumophilia, moraxella catarrhalis, mycoplasma pneumoniae, staphylococcus aureus and streptococcus pneumoniae. 2. upper respiratory tract infections: acute sinusitis due to streptococcus pneumoniae or haemophilus influenzae. acute streptococcal pharyngitis. note: penicillin is the usual drug of choice in the treatment of streptococcus pyogenes pharyngitis, including the prophylaxis of rheumatic fever. azithromycin appears to be almost as effective in the treatment of streptococcal pharyngitis. however, substantial data establishing the efficacy of azithromycin in the subsequent prevention of rheumatic fever are not available at present. 3. uncomplicated skin and skin structure infections: uncomplicated infections due to staphylococcus aureus, streptococcus pyogenes or streptococcus agalactiae. abscesses usually require surgical drainage. 4. sexually transmitted diseases: uncomplicated urethritis and cervicitis due to chlamydia trachomatis. . note: at the recommended dose azithromycin cannot be relied upon to treat gonorrhoea or syphilis. as with other medicines for the treatment of non-gonococcal infections, it may mask or delay the symptoms of incubating gonorrhoea or syphilis. appropriate tests should be performed for the detection of gonorrhoea or syphilis and treatment should be instituted as required. azithromycin is also indicated for the treatment of chlamydia trachomatis conjunctivitis and trachoma. azithromycin is also indicated for the prevention of infection due to mycobacterium avium-intracellular complex (mac) disease, when used as the sole agent or in combination with rifabutin at its approved dose, in adults and children aged more than 12 years with hiv infection and cd4 cell count less than or equal to 75 cells/microliter (see precautions). disseminated infection due to mycobacterium avium-intracellular complex should be excluded by a negative blood culture prior to commencement of therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - azithromycin dihydrate, quantity: 628.93 mg (equivalent: azithromycin, qty 600 mg) - tablet, film coated - excipient ingredients: pregelatinised maize starch; calcium phosphate; croscarmellose sodium; magnesium stearate; sodium lauryl sulfate; titanium dioxide; lactose monohydrate; hypromellose; triacetin - azithromycin is indicated for use in adults for the treatment of the following infections of mild to moderate severity: 1. lower respiratory tract infections: acute bacterial bronchitis due to streptococcus pneumoniae, haemophilus influenzae or moraxella catarrhalis. community acquired pneumonia due to streptococcus pneumoniae or haemophilus influenzae in patients suitable for outpatient oral treatment. community acquired pneumonia caused by susceptible organisms in patients who require initial intravenous therapy. in clinical studies efficacy has been demonstrated against chlamydia pneumoniae, haemophilus influenzae, legionella pneumophilia, moraxella catarrhalis, mycoplasma pneumoniae, staphylococcus aureus and streptococcus pneumoniae. 2. upper respiratory tract infections: acute sinusitis due to streptococcus pneumoniae or haemphilus influenzae. acute streptococcal pharyngitis. note: penicillin is the usual drug of choice in the treatment of streptococcus pyogenes pharyngitis, including the prophylaxis of rheumatic fever. azithromycin appears to be almost as effective in the treatment of streptococcal pharyngitis. however, substantial data establishing the efficacy of azithromycin in the subsequent prevention of rheumatic fever are not available at present. 3. uncomplicated skin and skin structure infections: uncomplicated infections due to staphylococcus aureus, streptococcus pyogenes or streptococcus agalactiae. abscesses usually require surgical drainage. 4. sexually transmitted diseases: uncomplicated urethritis and cervicitis due to chlamydia trachomatis. note. at the recommended dose azithromycin cannot be relied upon to treat gonorrhoea or syphilis. as with other drugs for the treatment of non-gonococcal infections, it may mask or delay the symptoms of incubating gonorrhoea or syphilis. appropriate tests should be performed for the detection of gonorrhoea or syphilis and treatment should be instituted as required. azithromycin is also indicated for the treatment of chlamydia trachomatis conjunctivits and trachoma. azithromycin is also indicated for the prevention of infection due to mycobacterium avium-intracellulare complex (mac) disease, when used as the sole agent or in combination with rifabutin at its approved dose, in adults and children aged more than 12 years with hiv infection and cd4 cell count less than or equal to 75 cells/microliter (see precautions). disseminated infection due to mycobacterium avium-intracellulare complex should be excluded by a negative blood culture prior to commencement of therapy. azithromycin is indicated for use in children for the treatment of the following infections: 1. acute streptococcal pharyngitis/tonsillitis. note: penicillin is the usual drug of choice in the treatment of streptococcus pyogenes pharyngitis, including the prophylaxis of rheumatic fever. the 20mg/kg azithromycin dose appears to be almost as effective as penicillin in the treatment of streptococcal pharyngitis. however substantial data establishing the efficacy of azithromycin in the subsequent prevention of rheumatic fever are not available at present. 2. chlamydia trachomatis conjunctivitis and trachoma in children 12 months or older.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - azithromycin dihydrate, quantity: 209.65 mg (equivalent: azithromycin, qty 200 mg) - suspension, powder for - excipient ingredients: sucrose; tribasic sodium phosphate; hyprolose; xanthan gum; flavour - azithromycin is indicated for use in adults for the treatment of the following infections of mild to moderate severity: 1. lower respiratory tract infections: acute bacterial bronchitis due to streptococcus pneumoniae, haemophilus influenzae or moraxella catarrhalis. community acquired pneumonia due to streptococcus pneumoniae or haemophilus influenzae in patients suitable for outpatient oral treatment. community acquired pneumonia caused by susceptible organisms in patients who require initial intravenous therapy. in clinical studies efficacy has been demonstrated against chlamydia pneumoniae, haemophilus influenzae, legionella pneumophilia, moraxella catarrhalis, mycoplasma pneumoniae, staphylococcus aureus and streptococcus pneumoniae. 2. upper respiratory tract infections: acute sinusitis due to streptococcus pneumoniae or haemphilus influenzae. acute streptococcal pharyngitis. note: penicillin is the usual drug of choice in the treatment of streptococcus pyogenes pharyngitis, including the prophylaxis of rheumatic fever. azithromycin appears to be almost as effective in the treatment of streptococcal pharyngitis. however, substantial data establishing the efficacy of azithromycin in the subsequent prevention of rheumatic fever are not available at present. 3. uncomplicated skin and skin structure infections: uncomplicated infections due to staphylococcus aureus, streptococcus pyogenes or streptococcus agalactiae. abscesses usually require surgical drainage. 4. sexually transmitted diseases: uncomplicated urethritis and cervicitis due to chlamydia trachomatis. note. at the recommended dose azithromycin cannot be relied upon to treat gonorrhoea or syphilis. as with other drugs for the treatment of non-gonococcal infections, it may mask or delay the symptoms of incubating gonorrhoea or syphilis. appropriate tests should be performed for the detection of gonorrhoea or syphilis and treatment should be instituted as required. azithromycin is also indicated for the treatment of chlamydia trachomatis conjunctivits and trachoma. azithromycin is also indicated for the prevention of infection due to mycobacterium avium-intracellulare complex (mac) disease, when used as the sole agent or in combination with rifabutin at its approved dose, in adults and children aged more than 12 years with hiv infection and cd4 cell count less than or equal to 75 cells/microliter (see precautions). disseminated infection due to mycobacterium avium-intracellulare complex should be excluded by a negative blood culture prior to commencement of therapy. azithromycin is indicated for use in children for the treatment of the following infections: 1. acute streptococcal pharyngitis/tonsillitis. note: penicillin is the usual drug of choice in the treatment of streptococcus pyogenes pharyngitis, including the prophylaxis of rheumatic fever. the 20mg/kg azithromycin dose appears to be almost as effective as penicillin in the treatment of streptococcal pharyngitis. however substantial data establishing the efficacy of azithromycin in the subsequent prevention of rheumatic fever are not available at present. 2. chlamydia trachomatis conjunctivitis and trachoma in children 12 months or older.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - azithromycin dihydrate, quantity: 524.1 mg (equivalent: azithromycin, qty 500 mg) - tablet, film coated - excipient ingredients: pregelatinised maize starch; calcium hydrogen phosphate; croscarmellose sodium; magnesium stearate; sodium lauryl sulfate; titanium dioxide; lactose monohydrate; hypromellose; triacetin - azithromycin is indicated for use in adults for the treatment of the following infections of mild to moderate severity: 1. lower respiratory tract infections: acute bacterial bronchitis due to streptococcus pneumoniae, haemophilus influenzae or moraxella catarrhalis. community acquired pneumonia due to streptococcus pneumoniae or haemophilus influenzae in patients suitable for outpatient oral treatment. community acquired pneumonia caused by susceptible organisms in patients who require initial intravenous therapy. in clinical studies efficacy has been demonstrated against chlamydia pneumoniae, haemophilus influenzae, legionella pneumophilia, moraxella catarrhalis, mycoplasma pneumoniae, staphylococcus aureus and streptococcus pneumoniae. 2. upper respiratory tract infections: acute sinusitis due to streptococcus pneumoniae or haemphilus influenzae. acute streptococcal pharyngitis. note: penicillin is the usual drug of choice in the treatment of streptococcus pyogenes pharyngitis, including the prophylaxis of rheumatic fever. azithromycin appears to be almost as effective in the treatment of streptococcal pharyngitis. however, substantial data establishing the efficacy of azithromycin in the subsequent prevention of rheumatic fever are not available at present. 3. uncomplicated skin and skin structure infections: uncomplicated infections due to staphylococcus aureus, streptococcus pyogenes or streptococcus agalactiae. abscesses usually require surgical drainage. 4. sexually transmitted diseases: uncomplicated urethritis and cervicitis due to chlamydia trachomatis. note. at the recommended dose azithromycin cannot be relied upon to treat gonorrhoea or syphilis. as with other drugs for the treatment of non-gonococcal infections, it may mask or delay the symptoms of incubating gonorrhoea or syphilis. appropriate tests should be performed for the detection of gonorrhoea or syphilis and treatment should be instituted as required. azithromycin is also indicated for the treatment of chlamydia trachomatis conjunctivits and trachoma. azithromycin is also indicated for the prevention of infection due to mycobacterium avium-intracellulare complex (mac) disease, when used as the sole agent or in combination with rifabutin at its approved dose, in adults and children aged more than 12 years with hiv infection and cd4 cell count less than or equal to 75 cells/microliter (see precautions). disseminated infection due to mycobacterium avium-intracellulare complex should be excluded by a negative blood culture prior to commencement of therapy. azithromycin is indicated for use in children for the treatment of the following infections: 1. acute streptococcal pharyngitis/tonsillitis. note: penicillin is the usual drug of choice in the treatment of streptococcus pyogenes pharyngitis, including the prophylaxis of rheumatic fever. the 20mg/kg azithromycin dose appears to be almost as effective as penicillin in the treatment of streptococcal pharyngitis. however substantial data establishing the efficacy of azithromycin in the subsequent prevention of rheumatic fever are not available at present. 2. chlamydia trachomatis conjunctivitis and trachoma in children 12 months or older.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - mycobacterium bovis (bacillus calmette and guerin (bcg) strain), quantity: 1.5 mg - injection, powder for - excipient ingredients: monosodium glutamate monohydrate - bcg vaccine is recommended for active immunisation in high risk groups. the nhmrc recommendation for bcg vaccination are: bcg is recommended for use in 3 groups of infants: . aboriginal and torres strait islander neonates in regions of high incidence; . neonates born to patients with leprosy; . children under the age of 5 years who will be travelling to live in countries of high tuberculosis prevalence for long periods. bcg vaccination should be considered for the following children and adolescents: .neonates who will be living in a household which includes immigrants or visitors recently arrived from countries of high prevalence (this also applies to neonates in families who have returned to visit the homes of relatives in countries of high prevalence); . children and adolescents aged less than 16 years who continue to be exposed to a patient with active tuberculosis, and where the child or adolescent cannot be placed on isoniazid therapy or the active case has organisms resistant to both isoniazid and rifampicin. in addition to the above categories, there are other groups of individuals who are at increased risk of tuberculosis, but for whom the value of bcg vaccine is less certain. these groups are: . health care workers with a high risk of exposure to tuberculosis, such as staff of chest clinics and tuberculosis wards, physiotherapists, diagnostic laboratory staff, autopsy room staff, and most medical and nursing staff of public hospitals; . travellers over the age of 5 years who will spend prolonged periods in countries of high tuberculosis prevalence. . a tuberculin test should be performed prior to bcg vaccination in all individuals, except in infants under 6 months of age. only subjects in whom a test dose of 10 units produces less than 5mm of induration should receive bcg. bcg vaccination has no value in the treatment of tuberculosis disease.

United States - English - NLM (National Library of Medicine)

dna labs, inc. - garlic (unii: v1v998dc17) (garlic - unii:v1v998dc17), aloe (unii: v5vd430yw9) (aloe - unii:v5vd430yw9), mycobacterium tuberculosis (unii: r0em8d5hfd) (mycobacterium tuberculosis - unii:r0em8d5hfd), eucalyptus globulus leaf (unii: s546ylw6e6) (eucalyptus globulus leaf - unii:s546ylw6e6), canis lupus familiaris milk (unii: g39p120jqt) (canis lupus familiaris milk - unii:g39p120jqt), cow milk (unii: 917j3173ft) (cow milk - unii:917j3173ft), rancid beef (unii: 29suh5r3hu) (rancid beef - unii:29suh5r3hu), - restoration of antibacterial system.

European Union - English - EMA (European Medicines Agency)

insmed netherlands b.v. - amikacin sulfate - respiratory tract infections - antibacterials for systemic use, - arikayce liposomal is indicated for the treatment of non-tuberculous mycobacterial (ntm) lung infections caused by mycobacterium avium complex (mac) in adults with limited treatment options who do not have cystic fibrosis.

United States - English - NLM (National Library of Medicine)

nutritional specialties, inc. - clostridium tetani (unii: 751e8j54vm) (clostridium tetani - unii:751e8j54vm), chlamydia trachomatis (unii: t6ni39qu44) (chlamydia trachomatis - unii:t6ni39qu44), escherichia coli (unii: 514b9k0l10) (escherichia coli - unii:514b9k0l10), klebsiella pneumoniae (unii: 09pa36ct5r) (klebsiella pneumoniae - unii:09pa36ct5r), mycobacterium avium subsp. paratuberculosis (unii: xh0f4ip2rx) (mycobacterium avium subsp. paratuberculosis - unii:xh0f4ip2rx), mycoplasma pneumoniae (unii: jqe470fad0) (mycoplasma pneum - aids in temporary relief of headache, runny nose, chills, minor cough, fatigue, and mild abdominal discomfort.† †claims based on traditional homeopathic practice, not accepted medical evidence. not fda evaluated. aids in temporary relief of headache, runny nose, chills, minor cough, fatigue, and mild abdominal discomfort.† †claims based on traditional homeopathic practice, not accepted medical evidence. not fda evaluated.